{
  "docId": "019de075-d6ea-7495-b63c-e64074d45b72",
  "docSlug": "3f99bbe59467be363a98d21e99cb078a",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 58 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 43,
  "pageCount": 58,
  "prevPage": 42,
  "nextPage": 44,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "Includes logos for BeiGene and Novartis at the bottom.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-d6ea-7495-b63c-e64074d45b72/43",
  "deckHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72",
  "deckJsonHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72.json",
  "deckAnchorHref": "/decks/019de075-d6ea-7495-b63c-e64074d45b72#slide-43",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.95,
        "x": 0.02,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Clinical trial flow chart showing monotherapy and combination therapy phases",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e16c2c7d-819f-47da-8e2a-7436ef03fa05",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.42,
        "x": 0.29,
        "y": 0.82
      },
      "kind": "image",
      "text": "BeiGene and Novartis logos",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "deaf03cb-e54c-4cf0-947b-7fa37a031c36",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.25,
        "y": 0.45
      },
      "kind": "metric",
      "text": "30 patients",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b418a2e3-5dd9-4316-b276-16d1c19bd635",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "IMX-110: Direct Path To 1st Line Therapy in STS – Clinical Trial Plan",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c8d64a6-294a-4712-8544-71c4ea966b25",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "7318758a-d8a8-45b2-8955-8a29fb46528f",
      "evidence": "The slide uses a horizontal flow to represent clinical trial phases over time.",
      "confidence": 0.7
    }
  ],
  "arcBeats": [
    {
      "to": 45,
      "from": 28,
      "beatId": "683cd8f0-b72b-44cb-97c1-04c1b9a9d852",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Desire",
      "beatSlug": "aida-desire",
      "evidence": "The deck highlights the benefits and potential of Immix Biopharma's therapies",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}